US EditionSetPoint Medical’s funding highlights investor confidence in neuromodulation approaches for autoimmune conditions: GlobalData - Express Healthcare
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
SetPoint Medical’s funding highlights investor confidence in neuromodulation approaches for autoimmune conditions: GlobalData - Express Healthcare
SetPoint Medical has recently secured $140 million in private financing to advance the commercial rollout of its SetPoint System, marking a major milestone in neuroimmune therapy for rheumatoid arthritis (RA). This funding underscores strong investor confidence in pioneering neuromodulation approaches to treating chronic autoimmune conditions, says GlobalData. The SetPoint System targets the body’s neural pathways to modulate the immune respons…
SetPoint Medical’s funding highlights investor confidence in neuromodulation approaches for autoimmune conditions, says GlobalData - GlobalData
SetPoint Medical has recently secured $140 million in private financing to advance the commercial rollout of its SetPoint System, marking a major milestone in neuroimmune therapy for rheumatoid arthritis (RA). This funding underscores strong investor confidence in pioneering neuromodulation approaches to treating chronic autoimmune conditions, says GlobalData, a leading data and analytics company. The SetPoint System targets the body’s neural pa…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
